Good morning, and welcome to Editas Medicine Second Quarter 2021 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company’s request. I would now like to turn the call over to Ron Moldaver, Investor Relations at Editas Medicine.

Thank you, Darryl. Good morning, everyone, and welcome to our second quarter 2021 conference call. Earlier this morning, we issued a press release providing our financial results and corporate updates for the second quarter of 2021. A replay of today's call will be available on the Investors section of our website approximately 2 hours after its completion. After our prepared remarks, we will open the call for Q&A. As a reminder, various remarks that we make during this call about the company's future expectations, plans, and prospects constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent annual report on Form 10-K, which is on file with the SEC. In addition, any forward-looking statements represent our views only as of today, and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change. Now I will turn the call over to our Chief Executive Officer, Jim Mullen.

Thanks, Ron, and good morning, everyone. I’m joined today by several members of the Editas executive team, including Mark Shearman, our new Chief Scientific Officer; Lisa Michaels, our Chief Medical Officer; and Michelle Robertson, our Chief Financial Officer. I want to start off by providing some highlights from the second quarter and reviewing our upcoming milestones. Editas had a strong first half of the year with excellent momentum across our platforms and lead programs. The EDIT-101 BRILLIANCE trial for LCA10 is proceeding very well with the Independent Data Monitoring Committee recently endorsing enrollment of the first of two planned pediatric cohorts. And we've also started enrolling patients in the adult high-dose cohort. We are also expected to share initial clinical data from the EDIT-101 trial this September. This will mark the company's first-ever clinical data readout. The RUBY study of EDIT-301 for sickle cell disease is screening patients and we remain on track to begin dosing by the end of the year. And the pre-IND work for EDIT-301 in beta thalassemia is progressing and we remain on track to file the IND before year-end. Additional data supporting the unique properties of our proprietary Cas12a enzyme was recently published in Nature Communications, and we plan to present new data on our multi-transgene knock-in proficiency at upcoming Cold Spring Harbor meeting. These accomplishments further support the incredible potential of our gene editing platform. Our manufacturing capabilities for lead programs have advanced nicely and we're ready to manufacture all clinical supplies for the RUBY trial. We continue to progress our oncology programs, including our iPSC-derived NK cell program that we are advancing in preclinical studies. And finally, we continue to make headway on our remaining preclinical programs, including ocular diseases. Additional updates on those programs will be provided later this year. On the…

Thank you, Jim, and thank you to everyone dialing in. So I'm thrilled to have joined Editas and to have the opportunity to lead an extremely experienced and dedicated group of researchers and scientists. My short time at the company has only reinforced my excitement in working with Jim, the rest of the leadership team and the exceptional people throughout the organization. To give you a brief background about myself, I've almost 30 years of drug discovery and development experience. And I've been fortunate enough to be a part of advancing around 15 drugs into clinical development. I began my career in academia, and then moved to the corporate R&D side where I conducted research into Alzheimer's disease, other neurodegenerative disorders as well as autoimmune diseases. For the last six years, I was the CSO at Applied Genetic Technologies Corporation, developing AAV gene therapies, mostly for ocular diseases. The impressive technology platform and the potential breakthrough capability of gene editing technology in the regenerative medicine space is what brought me to Editas. Most of my scientific work has revolved around ophthalmology, immunology, neurology, all key areas of development for this company. To be able to apply Editas's vast technological breadth towards my fields of expertise was truly a remarkable opportunity. I've always been intrigued by new aspects of sides of technology that can improve the likelihood of being successful in drug development, for which open new treatment avenues for patients who otherwise might not have other options. Editas's gene-editing platform has the potential for both of those. It allows us to address certain diseases, not easily addressed with other treatments, while also developing differentiated new medicines. This company has what I believe to be an unparalleled capability to edit the human genome and I'm excited to be part of its…

Thank you, Mark, and I wanted to simply say I'm excited to have you join us as part of our team. Okay, as part I'd like to start with an update on the BRILLIANCE trial for EDIT-101 for the treatment of LCA10. Last quarter, we completed dosing of the adult mid-dose cohort. And as Jim mentioned, we met with the study's Independent Data Monitoring Committee to review the safety data from the adult low-dose and mid-dose cohorts. The IDMC agreed with Editas that we could begin rolling the first of the two planned pediatric cohorts. And this is an important step in the trials since LCA10 is an early onset retinal degenerative disease, which results in vision loss and blindness at an early age. And we believe that younger participants in the study could provide the best opportunity to achieve the greatest magnitude of clinical benefit. As a reminder, LCA 10 is the most common cause of inherited childhood blindness. And it affects 3 out of every 100,000 children around the world. So new therapeutic options are urgently needed. And we continue to believe that a single administration would be preferred over a chronic dosing regimen by clinicians, parents, and occupation community. In addition to enrolling patients in the pediatric mid-dose cohort, we're also enrolling patients in the adult high-dose cohort. Both cohorts are planned to have four patients each, and we expect a complete dosing of the two dose groups in the first half of next year. We intend to present initial clinical data from EDIT-101 at the International Symposium at Retinal Degeneration in September. Now, this is an exciting milestone as it will be the first time that Editas will present clinical data at a meeting. The data will include safety and evaluation of the measures of biological…

Thanks, Lisa, and good morning, everyone. I'd like to refer you to our press release issued earlier today for a summary of our financial results in the second quarter, and I'll take this opportunity to briefly review a few highlights. Comparing with the first half of this year to last year, total operating expenses increased by approximately $25 million. This was primarily related to an increase in stock-based compensation of $14 million as well as a $9 million success payment due under one of our institutional licenses that was expressed [ph] in full during the first quarter of this year. The remaining increase is driven by our expanding critical regulatory and manufacturing efforts to support both our BRILLIANCE and RUBY trials and the pre-IND work for EDIT-301 to beta-thalassemia. Quarter-over-quarter, total operating expenses were $56 million in the second quarter compared to $63 million for Q1. Excluding stock-based compensation of $12 million in Q1 and $14 million in Q2, and the $9 million success payment in Q1, operating expenses were essentially flat in the first two quarters of this year. Editas's balance sheet and cash position remains very strong. Our cash balance as of June 30 was $698 million compared to $723 million at the end of Q1. This capital will allow us to execute on our strategy to progress our clinical programs, further develop our pipeline and continue to build our internal manufacturing capabilities. We anticipate that this cash position will fund our operation well into 2023. With that, I'll hand it back to Jim.

Thank you, Michelle. The first half of this year has been very productive for Editas and the gene editing community. We continue to see important accomplishments in the field including a successful demonstration of in vivo gene editing. This milestone reflects ongoing maturation of this novel therapeutic modality and immense potential for the technology. It supports the fundamental notion that a gene editing medicine administered directly to people can have a clinical benefit. And more importantly, this marks a monumental milestone for patients living with genetic diseases. Validating the potential power of CRISPR gene editing is a major stride forward for the genomic field and people who we are trying to help. As I've said in our previous call, it's truly a remarkable time to be involved in gene editing. I believe we have an obligation to utilize this once-in-a-generation technology to develop the best possible treatments for patients and promote progress within the scientific and medical communities. We thank all of you for your support and interest in the company. And with that, we'll open it up to questions-and-answers. Operator?

Thank you. We will now be conducting a question-and-answer session. [Operator Instructions] Our first question comes from the line of Gena Wang with Barclays. Please proceed with your question.

Thank you for taking my questions. I have two questions. The first one is regarding the LCA10 program. I think you mentioned the primary endpoint or like maybe a clinical measurement you will share. Just wondering like you mentioned visual acuity, wondering first of all, you also share mobility course score. And then, how should we look at this in the context of a natural history when you share the data? And the second question is regarding the 301 for sickle cell disease. Just wondering has the FDA partial clinical hold already resolved? And when you are seeing the on track dosing of first patient, do you expect that will be resolved by before year-end?

Lisa, are you there?

Pardon. Gena, I apologize, I was on mute. I was trying not to cough into my microphone. So to your first question, Gena, so regarding what's going to be reported in RD30 -- 301 -- for the EDIT-101 program moving into the RD2021 meeting. So I've already summarized, the meeting is -- that the primary outcome of the study really remains safety and dose-limiting toxicity. So the data and the cumulative safety data of the patients who've been dosed in the first two cohorts will definitely be presented at that meeting. What I want to remind people is that this is still an ongoing study moving forward over time, and that we collect quite large number of observations with two primary goals. The first one is for the purposes of being able to demonstrate that editing has actually occurred in the eyes. And that will be a very interesting proof-of-concept for us to share regarding any potential changes that have occurred either in the anatomy of the retina, or also reflections of responses the retina to light. The second one regarding the efficacy outcomes that you've measured -- that you've alluded to such as BCVA and also for being able to maneuver in the maze. I want to remind everybody, it's still quite early in the trial. The longest patient in the mid-dose cohort was only dosed in January. So we're still collecting data prospectively. It's certainly our intent to look across the entire range of measurements in each individual patient moving forward, and that we will be sharing at least data that will be comprehensively looking at both the possibility of being able to show both efficacy as well as clinical outcomes at the study. Beyond that, I'm not yet prepared to give you more detail. To the second question, with 301, I just kind of remind everybody, it's not a complete clinical hold, it is a partial hold basically in order to be able to validate the clinical assays that we're using to correlate dosing to clinical efficacy. It does not interfere at all with our ability to move forward. We are able to dose the patients in the trial in an ongoing fashion as already outlined in the protocol. And so it's actually having no impact on our ability to move forward. We will need to have some patient data to correlate in order to be able to lift the hold with the agency later on.

Thank you.

Yes.

Thank you. Our next question comes from the line of Matthew Harrison with Morgan Stanley. Please proceed with your questions.

Good morning, everyone. This is Costa Sean for Matthew. One question from us on EDIT-101. Can you please remind us what the stopping criteria in the high-dose cohort? Thank you.

So the stopping criteria is very clear across all different dose cohorts. And that is basically the dose-limiting toxicity. This would include inflammatory responses that cannot be controlled with the use of steroids and would also include any potential loss in visual acuity in any patient who has something that's measured.

Thank you.

Thank you. Our next question comes from the line of Phil Nadeau with Cowen & Company. Please proceed with your questions.

Good morning. Congrats on the progress. A follow-up question for me on 101. In the -- in your corporate presentation, you mentioned secondary efficacy endpoints in 101s trial, including macula thickness, electroretinogram and pupillometry. It sounds like you're going to use those to figure out if there's sufficient editing going on in the retina. As I'm not at all that familiar with those measures, can you give us some idea of what changes you'd need to see to have confidence that there's a sufficient amount of editing in vivo, that there could be ultimately improvements of visual acuity in a young enough patient population.

Okay. So basically, the way I've been dividing it up is and I think you summarized it actually quite well. The first one is a lot of electrophysiologic measurements as well as mineralizing physiologic responses to either different colors of light. Pupillary responses to light being shined in the eyes, because these patients do tend to have either reduced or very sluggish responses. If we were to see consistent changes moving forward in any of those measures that at least would be a signal to us that editing is taking place in the back of the eye. This is sort of my indirect way of measuring it without the ability to actually measure the protein that's being created in the eye moving forward. As to the clinically relevant endpoints, I would agree with those that say that basically, definitely those are things that impact a patient's ability to function, such as visual acuity or also the ability to maneuver around the maze would be the approval endpoints and the ones that would bring most value to the patient.

Perfect. Another follow-up question on 301. And the answer to the last question, it sounds like you'll need some clinical data to validate the assays necessary to remove the clinical hold. Do you have a definitive agreement with the FDA and the amount of clinical data that's necessary, the number of patients or duration?

So at the moment, we have at least proposed a matrix in order to be able to show how the -- across multiple different measures to show consistency of the product being given to the patients. The plan is to actually be able to present that to the agency once we have data to support it.

Perfect. Thanks for taking our questions.

Thank you. Our next question come from the line of Yanan Zhu with Wells Fargo. Please proceed with your question.

Thanks for taking my questions. So on the biomarkers for lack of better words, the several measures that you will investigate to see -- to understand whether there's editing. Do we know that those measures -- do they change by - simply by a subretinal injection, for example? Or do they change based on a placebo type response? Do we have some understanding of how reliable those biomarkers are? Thanks.

So -- and I invite Mark to jump in if he feels like he wants to add color to it. But I think one of the most important things for us is, first of all, the biologic markers are basically physiologic responses. So these are purely objective measures that we can actually measure physiologic changes that can take place. The concern about placebo is that it is unblinded both the treater and the patient, both know of which eye has been treated. And this is the primary reason why we're actually focusing on reproducibility. A one-time measurement that shows a significant change in vision is not going to be enough for us, it really needs to be able to be sustained across multiple different measures over time.

Yes. And if I could add up, thanks for the question, Yanan. As you know from covering the companies that are administering subretinal AAV, there is a possibility of slight changes in and around the surgical procedure as the retinue reestablish and reattaches. Those are usually tracked by comparing the untreated. And as Lisa pointed out, over time, they generally settled down within a couple of weeks. And so, all of that data gets collected and tracked and the intention is to show over time a real treatment effect that's separate from a surgical line or any other intervention related page.

Got it. That's very helpful. And for, you mentioned, the longest follow-up in mid-dose cohort is since January. What about the shortest follow-up? It does have that patient finish? Will that patient have finished the 3 months efficacy evaluation by the time of presentation.

I can tell you we're coming down to the wire on that one. So I need to be able to see what the timing of that visits going to be.

Great. Thank you.

Yes.

Thank you. Our next question comes from the line of Cory Kasimov with J.P. Morgan. Please proceed with your questions.

Hey, good morning, guys. Thanks for taking the question. My question is on 101 and 301 recovered. So wanted to ask about the iPSC NK program. And if you could just update us on the progress you're making there and upcoming milestones, we should be on the lookout for. Thank you.

Mark, do you want to handle that one?

Yes. So, we've indicated in the corporate presentation some of the changes that are being made. And we continue to develop the necessary editing for the final construct, and also the differentiation profile and process for that. And so right now that's really what we're focused on, and we'll be providing updates again later in the year on the progress.

Thank you. Our next question come from the line of Joon Lee with Truist Securities. Please proceed with your questions.

Hi. Thanks for taking our questions. For the cohort two, are the patients enrolled also light perception only, like cohort one or are they able to perceive hand motion or better in the cohort two. And I have a follow-up on 301.

Okay. So for 101 the way the protocol is basically written as we were able to -- based upon the safety that was seen in the first cohort, we were able to modify the protocol so that we can proceed beyond just like perception patients. However, each dose level we do have one sentinel patient who is enrolled primarily for the purposes of evaluating safety and making sure there's no inflammatory reactions that would limit treatment of further patients. So the first patient is light perception, but each additional patient enrolled can have better visual acuity.

Okay. So just following up on that, if you look at the [indiscernible] data their visual improvements including BCVA and mobility evident as early as month one and two, is there any reason to believe that the effects of at 101 would be any slower than the antisense mediated Exon skipping. Curious if you have any thoughts in the genetics of the onset of clinical side between genome editing versus [indiscernible]?

So I guess the way if you're thinking in terms of the absolute timing, we do know that from a non-clinical data that the optimal editing has occurred by about 6 weeks after injection. As Mark has alluded to, they’re also because of the procedure needs to be some healing that needs to take place in the back of the eye. So the first measurement that we would expect to see some change would be at 3 months. However, because we're really looking for consistent responses as well as potential improvement, following it out to at least 6 months or longer is going to be what we're going to be looking at. But is there any -- it's hard to compare the two different modalities, it's very different approaches.

Got it. And just for clarification, the cohort two will be four patients worth of data?

So each cohort is planned to be four patients and then we'll evaluate.

Okay. Thank you.

Yes.

Thank you. Our next question come from the line of Tiago Fauth with Credit Suisse. Please proceed with your questions.

Hi. This is Jonathan on for Tiago. Thanks for taking our question. For EDIT-101 in light of the upcoming readout for the low and mid-dose cohorts for the adults, how should we be thinking about how these results may translate to the respective doses in the pediatric cohorts? What are the key differences we should be thinking about that? Thanks.

I think we still have yet to kind of learn that in terms of the observations. In general, the maturity of the human eye after you get about 3 years of age, at least the anatomy and the size of the eye are relatively similar. Most of the changes that occur in the eye are more or less completed by about 6 to 8 years of age. So I'm not -- I don't know that we're going to see a difference in terms of clinical response or safety. We'll have a chance to evaluate that as we move forward.

Got it. Thank you very much.

Yes.

Thank you. Our next question comes from the line of Steve Seedhouse with Raymond James. Please proceed with your question.

Good morning. Thank you. [Indiscernible] 301, I'm just curious beyond editing efficiency, what advantages you might anticipate from using the AsCas12a in sickle cell specifically, like cell viability, doubling time manufacturing success rate, things like this compared to legacy nucleases that may obviously correspond to improve clinical outcome? And then also on the ultra nuclease, it looks like it's small enough to package into AAV5. Any thought on advancing that nuclease into LCA10, or in future ocular disorders is just a nuclease as you're planning on using? Thanks.

So, maybe I can take those questions. So as you saw in the Nature Communications paper, the Cas12 -- engineered Cas12a or Cas12a Ultra has a lot of very favorable properties. You mentioned some of them, specificity, the on target editing, efficiency, potency, all of that. One other factor, which is important for us also is the guide RNA size tends to be quite a bit smaller than the Cas9 guides and that's important when you're manufacturing these guide RNAs because the fidelity decreases the longer the length of the guides. And so we feel that that is definitely an advantage for intrinsic on target editing. And the second part of your question, of course, yes, we can fit a Cas12a into an AAV and so we're looking to deploy that in some of the in vivo gene editing programs that we have ongoing and potential future ones and actively working on optimizing the potential configurations that you could use with respect to the guides. So all of that is in progress.

Thank you. Our next question come from the line of Joel Beatty with Citi. Please proceed with your questions.

Hi, this is [indiscernible]. Thanks for taking the questions. For the LCA10 program in the pediatric mid-dose cohort, what ages and what status of disease [indiscernible] in the children? Do you anticipate in enrolling and what could that mean for the ability to interpret clinical results compared to the first cohort, that we'll be reading out in September?

So we've got a little bit of a balancing act in all of this, because the protocol does allow us to go as young as 3 years of age in the treatment of the patients. But I think one of the key outcomes that we want out of this is just not -- it's not just safety. But it's also the ability of the patient to be able to cooperate with the various different observations, because what we're looking for at the end of the day is a clear signal of efficacy. So the selection of the first patients who will be treated in the cohort are being considered about their ability to participate in the observations. And I think there's no solid drawn line in here, but if you think about your 5 or 6 year old, whether they can sit through a long day of observations and walking through [indiscernible] I think as part of our consideration.

Okay. Appreciate that. Thanks.

Yes.

Thank you. Our next question come from the line of Jay Olson with Oppenheimer. Please proceed with your question.

Oh, hey, congrats on the progress and thank you for taking our questions. On the EDIT-101 data coming in September, can you talk about whether or not we should expect to see the clinical measurements fluctuate over the follow-up period or remain relatively consistent? And then for any safety signals, are there ways to tell whether potential side effects are coming from the administration procedure, the AAV vehicle or the gene editing? And then I had a follow-up on SCD, if I could.

Okay. So I guess the first one is the consistency of measures. I just want to remind everybody, it's still relatively young days for that middle-dose cohort. Because like I said, the first patient was started in June and the next 3 patients were enrolled over the following 5 months. So for some of these patients, we won't have that much reproducible data just yet. As for the safety observations, it is one of the more important observations of the trial, not just short-term toxicity related to inflammation or problems related to the administration of the product, but also any changes that might occur in the eye moving forward. So that data is being collected prospectively.

Great. Thank you. And then for 301 in the SCD study, can you just talk about your timeline for completing the target enrollment in that study? And then maybe comment on what the FDA might want to see in terms of a follow-up period in SCD given some potential safety concerns from other companies using gene therapy?

So the second half of the question is we are expecting and in fact, it's sort of standard across the entire gene therapy and gene editing space that long-term follow-up for safety will be a requirement. So pharmacovigilance is going to be something that all of us have to be addressing moving forward. As to our timeline, it's still again early days. We actually are actively opening up sites. We have a number of patients who are undergoing screening, and I'm focusing mostly on getting my first patient dose by the end of this year.

Great. Thanks for taking the question.

Yes.

Thank you. Our next questions come from the line of Madhu Kumar with Goldman Sachs. Please proceed with your questions.

Great. Thanks for taking our questions. So when we think about EDIT-101 the high dose versus a median low-dose, frame those doses relative to the preclinical dose range you described in your previous studies. And then kind of following from that, what [technical difficulty] you confident that a higher dose of 101 could achieve better outcomes for LTA patients? Thanks.

Mark, do you want to try that one, or you want me to bite?

No. The doses, as I'm sure you've already asked a similar question, for the doses chosen for the clinical study we're obviously guided by the preclinical pharmacology and toxicology work that was done in mouse and non-human primate. The -- to address the question about whether we think a higher dose will lead to better editing, we have evidence, particularly in the human [indiscernible] model that would be the case. I think in non-human primates there is some indication that that could also occur. The data was, I would say, less clear in terms of the fact that the NHP guides were not performing as effectively as the human ones. But in principle, yes, the expression of the nuclease components and the editing -- productive editing increased with dose. And so going from the mid to high-dose, which is a factor of three. Going into it, we would have an expectation that could yield better results. But obviously, the clinical data will have to bear that out.

Thank you. Our next questions come from the line of Liisa Bayko with Evercore. Please proceed with your question.

Hi. Thanks for taking the question. I'm wondering as you think about the kind of available visual field for these patients for EDIT-101, can you maybe describe kind of with the way you're administering, how much is kind of, I don't know, in a way surface area would be available for editing? And is there anything you can do to kind of expand that further?

I guess, I will start with -- go ahead, Mark. We can fight each other for this, what if you want.

Across different fields where companies have introduced a bleb up to, for example, 300 [indiscernible] covering about a 20 degree area, so completely covering the maxilla, which is the important component here for ability to restore cone [ph] function. So I hope that answers your question. But that's the intent with the current dosing paradigm.

Okay. So what you're saying is you can cover the entire macula with that -- with a bleb and so that should be sufficient in terms of like, kind of covering the visual field in a way.

Well, that's covering the majority, if not all of the cones expression, which are obviously content in the maximum [indiscernible] region, plus the rods, which also expressed more sparsely but expressed in that area. So again, this is, I would say, the standard approach to covering central retina AAV treatments.

Okay. And I would say that LCA10 is somewhat of a central retina, basically what's happened in many of these patients is there is a preserved area of cells of normal cells where there hasn't been degeneration. And actually, that's in the central retina itself. So these are the cells that are most likely the ones that we're going to have the best effect from?

Yes.

Okay.

And maybe just to [technical difficulty] I mean, companies have attempted to put the bleb either outside the mid periphery, or in some cases, multiple blabs for the former approach. The disease quite often is heterogeneous in the periphery. So it's not that straightforward to actually carefully cover the degenerative rod area if that's what you were attempting to do. And then the challenge with the multiple bleb approaches on the one hand, yes, you can cover a greater area, but then you're introducing multiple retinotomies and one of the things you absolutely want to avoid is reflux of the product because as you may be aware, intravitreal dosing, which essentially what's been happening leads to a greater likelihood of ocular inflammation. So those are the tradeoffs that you're considering.

Okay. Okay, that's helpful. Thank you. And then for EDIT-301, as you kind of look at the data, the clinical data coming out from companies like Vertex, CRISPR and where do you see the opportunity? I know theoretically the kind of advantages you're describing and those make sense, but sort of in a practical form as you kind of look at the data that's evolving, where do you see the opportunity to make a difference with EDIT-301? Thank you.

[Indiscernible] that one, Lisa?

So I would say -- well, you always answer it really well. I’m [multiple speakers] you usually answer it really well. So …

Well, yes. So I will take that one. This is Jim. I think you have to take a little bit longer view of what trials in sickle cell and beta-thalassemia are attempting to accomplish, which is ultimately long-term morbidity and mortalities or organ damage and extension of life, which is a big issue for these patients. So I think, as you see things unfold, yes, the initial data coming out of the other companies is actually impressive, and that's great for the patients. But I think we have to see how this unfolds over a longer period of time. And so I would expect that this field, there'll be long-term efficacy and safety studies used in this field. And that's how things will differentiate. And then ultimately, as efficacy demonstrated, and the safety is demonstrated, the companies are going to go to work and some already are. What are the conditioning strategies or basically how to make the treatment burden as light as possible for patients? And that may also relate to the drug, the simplicity of the drug, how much drug you have to deliver, how many cells you have to collect, etcetera, etcetera. So I think there's a number of other variables that will come into play as things unfold.

Thank you. Our next questions come from the line of Luca Issi with RBC. Please proceed with your questions.

Terrific. Thanks so much for taking my question. Congrats on all the progress. Two quick one. One from -- for Lisa and Mark, and the other one for Jim. So for Lisa, Mark, you're obviously using AAV to deliver your construct. I think the FDA is having an advisory committee meeting, September 2 and 3 to talk about the safety of AAV. So wondering, one, if you're planning to participate in that AdCom? And two, what are your expectation getting into that event? And maybe, Jim, for you a bigger picture, what's the latest thinking of business development, when you think about the three kind of big dimension of your pipeline, which is obviously the eye, hemoglobinopathies and oncology, which of them you think are going to be core to editor story going forward versus which one may be you're willing to partner and maybe on the in-licensing side, do you have any appetite to actually bolster your pipeline via BD [ph]? Thanks so much.

So maybe I can take the first question. Yes, we will be participating in the FDA meeting to discuss some emerging issues with AAV. What I would say to answer kind of the second part of that is, people are using a vehicle multiple, very different approaches, and at significantly different amounts. And so I think the ocular space, one of the reasons why this was one of the first areas that people use AAV as a delivery vehicle is because you can -- there's a very defined anatomy, you can deliver the product very carefully to the right place, and it's at relatively low amounts, 100 to 1,000 of the dose that some of the other systemic administration they’re using. So I think that meeting will be important. I think, some aspects of it around [indiscernible] integration or immunogenicity are probably more relevant for the DMV and the hemophilia folks were they’re using much higher levels and you do clearly have immune related response. But the meeting will result in some guidelines and some further direction and that's obviously important to be aware of and if it becomes relevant for SSRS will fully participate and be part of that.

So, Luca, let me take the second part of that which is sort of BD strategy overall. So in addition to building the leadership group that I talked about early in this call, we have also been building depth below that leadership group. And so, for the first time and now, Mark is here, I'm thrilled to have Mark. Lisa is getting a little bit of bandwidth to start thinking about, sort of the broader strategy. And we've appointed Bruce Eaton, that we've really got the team together now to really rigorously sort of think about strategy. Now, let me take it to the sort of how we're thinking about BD. I have I've been in the industry a long time, and so I'm fairly pragmatic about what do we think we can execute? And let's -- and what do we think we will ultimately need help with. So we've got a nice productive relationship with BMS on the T cell side of oncology. We've made, I think, pretty significant advancements on our iPSC-derived NK platform. But there's an area where I think going into clinical development, and certainly, further into clinical development and commercial, that we will be best served, if we have a partner in that. So that will be something that we will look to. It's always hard to judge exactly right, what the right moment in time is do that. But that will be a high priority. Similarly, with the 301 program, I feel very comfortable that we can advance that one clinically. But ultimately, we would want a commercial partner, particularly ex U.S. And certainly, I also know that that means if you give a commercial partner, they're going to want to participate at some meaningful level in the late stage development, right. So those would be sort of two bigger pieces. With respect to thinking about in-licensing things we are actively talking about that I think that can come in different flavors and forms we have, as you know, what I consider the sort of the biggest challenge in gene editing is -- we in a weakened edit, we know that it's -- can you get the editing machinery to the right or again, or the right cell type at the right efficiency with an appropriate safety profile. And so, when you think about our three programs, right, they are in some ways, three different ways of delivering editing as a therapeutic. But we'll look at additional one. So AAV, as good as it is, has its own limitations. We've seen other people with [indiscernible] for the right indications [indiscernible] and/or other different delivery modalities are certainly something we'd look at. And then lastly, things that potentially complement either our technology or a therapeutic area where we have an interest, for example, ocular where we have a number of programs, we'd certainly look to think about augmenting the depth of our pipeline there. Hopefully that helps.

Fantastic. Yes, thanks so much. Appreciated.

Yes.

Thank you. There are no further questions at this time. I would like to turn the call back over to management for any closing remarks.

Well, thank you very much, everyone. A lot of great questions today. Really appreciate all the interest. We will have -- I know a number of conversations here over the upcoming days, and I greatly look forward to talking with all of you in the future. Thanks again and I think we will call it a day. Appreciate your time. Take care. Bye.

Thank you for your participation. This does conclude today's teleconference. You may disconnect your lines at this time. Have a great day.